{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:38:14Z","timestamp":1792528694365,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":282,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031949","name":"Guardant Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101479","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:06:08Z","timestamp":1792163168000},"page":"101479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world analysis of treatments, healthcare costs, and overall survival among patients with metastatic non-small cell lung cancer by molecular biomarker testing approach"],"prefix":"10.1016","volume":"49","author":[{"given":"Julie A.","family":"Wiedower","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Stockl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun P.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keelia","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Certa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101479_bib0001","article-title":"Non-small cell lung cancer","author":"Riely","year":"2025","journal-title":"NCCN Clin. Pract. Guidel."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101479_bib0002","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.21.02767","article-title":"Somatic genomic testing in patients with metastatic or advanced cancer: ASCO Provisional Clinical Opinion","volume":"40","author":"Chakravarty","year":"2022","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101479_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.38219","article-title":"Trends in use of next-generation sequencing in patients with solid tumors by race and ethnicity after implementation of the Medicare national Coverage determination","volume":"4","author":"Sheinson","year":"2021","journal-title":"JAMa Netw. Open."},{"key":"10.1016\/j.ctarc.2026.101479_bib0004","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2022.03.004","article-title":"Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network","volume":"166","author":"Robert","year":"2022","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101479_bib0005","article-title":"Biomarker testing for patients with advanced\/metastatic nonsquamous NSCLC in the United States of America, 2015 to 2021","volume":"3","author":"Hess","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101479_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10809","article-title":"Practice-level variation in molecular testing and use of targeted therapy for patients with non\u2013small cell lung cancer and colorectal cancer","volume":"6","author":"Roberts","year":"2023","journal-title":"JAMa Netw. Open."},{"key":"10.1016\/j.ctarc.2026.101479_bib0008","article-title":"Impact of clinical practice gaps on the implementation of personalized medicine in advanced non-small-cell lung cancer","volume":"6","author":"Sadik","year":"2022","journal-title":"JCo Precis. Oncol."},{"key":"10.1016\/j.ctarc.2026.101479_bib0009","first-page":"1417","article-title":"Clinical and economic outcomes by first-line treatment among women with HR+\/HER2- metastatic breast cancer in a large US health plan database","author":"Burton","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.ctarc.2026.101479_bib0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13569-017-0084-4","article-title":"A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the US","volume":"7","author":"Villalobos","year":"2017","journal-title":"Clin. Sarcoma Res."},{"key":"10.1016\/j.ctarc.2026.101479_bib0011","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/07357907.2020.1827415","article-title":"Real-world outcomes and value of first-line therapy for metastatic non-small cell lung cancer","volume":"38","author":"DaCosta Byfield","year":"2020","journal-title":"Cancer Invest."},{"key":"10.1016\/j.ctarc.2026.101479_bib0012","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1634\/theoncologist.2018-0018","article-title":"Cost of disease progression in patients with metastatic breast, lung, and colorectal cancer","volume":"24","author":"Reyes","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2026.101479_bib0013","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1634\/theoncologist.2018-0019","article-title":"Cost of disease progression in patients with chronic lymphocytic leukemia, acute myeloid leukemia, and non-Hodgkin\u2019s lymphoma","volume":"24","author":"Reyes","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2026.101479_bib0014","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/s12325-019-0890-6","article-title":"Real-world treatment patters among patients initiating small molecule kinase inhibitor anticancer treatments for thyroid cancer in the United States","volume":"36","author":"DaCosta Byfield","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ctarc.2026.101479_bib0015","unstructured":"US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Medical Care. Series ID: CUUR0000SAM. Washington, DC: U.S. Dept. of Labor, Bureau of Labor Statistics. 2022 http:\/\/data.bls.gov\/cgi-bin\/surveymost?cu."},{"key":"10.1016\/j.ctarc.2026.101479_bib0017","unstructured":"United States Census Bureau. Geographic levels. 2022-2023 https:\/\/www.census.gov\/programs-surveys\/economic-census\/guidance-geographies\/levels.html."},{"key":"10.1016\/j.ctarc.2026.101479_bib0018","article-title":"Real-world impact of comprehensive genomic profiling on biomarker detection, receipt of therapy, and clinical outcomes in advanced non-small cell lung cancer","volume":"8","author":"Wallenta Law","year":"2024","journal-title":"JCo Precis. Oncol."},{"key":"10.1016\/j.ctarc.2026.101479_bib0019","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101479_bib0020","doi-asserted-by":"crossref","DOI":"10.1200\/PO.20.00241","article-title":"Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non-small-cell lung cancer","author":"Palmero","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ctarc.2026.101479_bib0021","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2022.05.012","article-title":"Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients","volume":"171","author":"Cui","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101479_bib0022","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cllc.2021.10.001","article-title":"Clinical outcomes for plasma-based comprehensive genomic profiling versus standard of care tissue testing in metastatic non-small cell lung cancer","volume":"23","author":"Page","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101479_bib0023","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-22-1749","article-title":"A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid)","volume":"29","author":"Sugimoto","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101479_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113310","article-title":"Upfront liquid next-generation sequencing in treatment-na\u00efve advanced non-small cell lung cancer patients: a prospective randomized study in the Taiwanese health system","volume":"193","author":"Yang","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101479_bib0025","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40291-024-00725-x","article-title":"Clinical validity and utility of circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): a systematic literature review and meta-analysis","volume":"28","author":"Chen","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ctarc.2026.101479_bib0026","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00191","article-title":"Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non-small-cell lung cancer","author":"Aggarwal","year":"2023","journal-title":"JCO Precis. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101479_bib0027","doi-asserted-by":"crossref","first-page":"934","DOI":"10.6004\/jnccn.2023.7039","article-title":"Biomarker testing, treatment, and outcomes in patients with advanced\/metastatic non-small cell lung cancer using a real-world database","volume":"21","author":"Bhandari","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ctarc.2026.101479_bib0028","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/OP.22.00611","article-title":"Compromised outcomes in stage IV non-small-cell lung cancer with actionable mutations initially treated without tyrosine kinase inhibitors: a retrospective analysis of real-world data","volume":"20","author":"Scott","year":"2024","journal-title":"JCO Oncol Pr."},{"issue":"1D","key":"10.1016\/j.ctarc.2026.101479_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6004\/jnccn.2023.7073","article-title":"Associations among optimal lung cancer treatment, clinical outcomes, and health care utilization in patients who underwent comprehensive genomic profiling","volume":"22","author":"Powell","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ctarc.2026.101479_bib0030","first-page":"S439","article-title":"Understanding total cost of care in advanced non-small cell lung cancer pre- and post-approval of immune-oncology therapies","volume":"24","author":"Korytowsky","year":"2018","journal-title":"Am. J. Manage Care"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101479_bib0031","first-page":"729","article-title":"Real-world costs of adverse events in first-line treatment of metastatic non-small cell lung cancer","volume":"26","author":"Engel-Nitz","year":"2020","journal-title":"J. Manage Care Spec. Pharm."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101479_bib0032","doi-asserted-by":"crossref","first-page":"e1225","DOI":"10.1200\/OP.20.01092","article-title":"Effect of clinical trial participation on costs to payers in metastatic non-small-cell lung cancer","volume":"17","author":"Merkhofer","year":"2021","journal-title":"JCO Oncol Pr."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101479_bib0033","first-page":"255","article-title":"Health care resource utilization and costs associated with advanced or metastatic non-small cell lung cancer in the United States","volume":"28","author":"Zhang","year":"2022","journal-title":"J. Manage Care Spec. Pharm."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101479_bib0034","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.37765\/ajmc.2023.89360","article-title":"Better together? Costs of first-line chemoimmunotherapy for advanced non-small cell lung cancer","volume":"29","author":"Kish","year":"2023","journal-title":"Am. J. Manage Care"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101479_bib0035","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s41669-023-00407-0","article-title":"Healthcare resource utilization and costs in patients with EGFR-mutated advanced non-small cell lung cancer receiving first-line treatment in the United States: an insurance claims-based descriptive analysis","volume":"7","author":"Vanderpoel","year":"2023","journal-title":"Pharmacoecon. Open."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101479_bib0036","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1007\/s12325-024-03020-7","article-title":"Real-world evaluation of treatment patterns, healthcare costs, and healthcare resource utilization among patients with non-small cell lung cancer in the US receiving sotorasib","volume":"41","author":"Sultan","year":"2024","journal-title":"Adv. Ther."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101479_bib0037","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/13696998.2022.2154479","article-title":"Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study","volume":"26","author":"Hess","year":"2023","journal-title":"J. Med. Econ."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101479_bib0038","first-page":"660","article-title":"Real-world clinical and economic outcomes for patients with advanced non-small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy","volume":"30","author":"Wiedower","year":"2024","journal-title":"J. Manage Care Spec. Pharm."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101479_bib0039","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/1878-0261.13038","article-title":"Cost-effectiveness of precision diagnostic testing for precision medicine approaches against non-small-cell lung cancer: a systematic review","volume":"15","author":"Henderson","year":"2021","journal-title":"Mol. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101479_bib0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2217\/fon-2021-1040","article-title":"Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review","volume":"18","author":"Zheng","year":"2022","journal-title":"Future Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101479_bib0041","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmoldx.2022.04.010","article-title":"Diagnostic value and cost-effectiveness of next-generation sequencing-based testing for treatment of patients with advanced\/metastatic non-squamous non-small-cell lung cancer in the United States","volume":"24","author":"Zou","year":"2022","journal-title":"J. Mol. Dian."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101479_bib0042","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/13696998.2024.2314430","article-title":"Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer","volume":"27","author":"Bestvina","year":"2024","journal-title":"J. Med. Econ."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:40:34Z","timestamp":1792525234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":40,"alternative-id":["S2468294226003886"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101479","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world analysis of treatments, healthcare costs, and overall survival among patients with metastatic non-small cell lung cancer by molecular biomarker testing approach","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101479"}}